Cook's Zilver PTX stent
This article was originally published in The Gray Sheet
Executive Summary
Cook Medical submits PMA application to FDA for its Zilver PTX paclitaxel-eluting stent to treat peripheral arterial disease in the superficial femoral artery. The polymer-free, self-expanding nitinol stent debuted in Europe last fall. Recently reported results of a prospective, single-arm study showed that at 12 months, freedom from target lesion revascularization was 90.5% (1"The Gray Sheet" May 17, 2010)